Exploring the Light/dark Box Test: Protocols and Implications for Neuroscience Research
Overview
Authors
Affiliations
Background: Knowledge on the neurobiological systems underlying psychiatric disorders has considerably evolved due to findings on basic research using animal models. Anxiety-like behaviors in rodents are widely explored in neuroethological apparatuses, such as the light-dark box (LDB) test through different protocols, which have been shown to influence the behavioral outcomes and probably the activation of the hypothalamic-pituitary-adrenal (HPA) axis.
New Method: Adult male Wistar rats were submitted to LDB in different room illumination conditions (25/0, 65/0 and/or 330/0 lux), initial positioning in the LDB compartments and previous stressful experience in the Elevated Plus Maze (EPM) or restraint stress (RS). Rats' behavior (exploratory and risk assessment) was registered during a 15 min period, divided into blocks of 5 min RESULTS: Exploration of the lit compartment decreased in higher luminosity condition, as after positioning rats in the dark compartment or previous exposure to the EPM, while low luminosity increased exploration of the LDB. No differences were observed on serum corticosterone in all groups and experimental conditions.
Comparison With Existing Methods: Light intensity and test duration influenced exploration of the LDB jeopardizing the anxiolytic/anxiogenic effects. Low light intensity increased exploration, while high intensity decreased it. These results suggest that 65/0 lux is a neutral condition to investigate possible anxiolytic/anxiogenic effects of drugs and/or exposure to previous aversive stimuli as the EPM.
Conclusions: Different factors impact on exploratory and risk assessment behaviors which may be related to safety maximization behavior. Unraveling how different factors affect behavior may be a crucial step towards understanding its expression and the contributions on advances in the physiopathology 1 and treatment of psychiatric disorders.
Phytochemical screening and neuro-pharmacological activity of flowers: Integrating , and approaches.
Alam F, Alam R, Yusuf A, Ripa J, Nithin R, Barua S Heliyon. 2025; 11(3):e42017.
PMID: 39975813 PMC: 11835627. DOI: 10.1016/j.heliyon.2025.e42017.
Di Marino C, Llorente-Berzal A, Diego A, Bella A, Boullon L, Berrocoso E Front Pharmacol. 2025; 15():1505980.
PMID: 39830350 PMC: 11739114. DOI: 10.3389/fphar.2024.1505980.
Smirnova K, Amstislavskaya T, Smirnova L Int J Mol Sci. 2024; 25(22).
PMID: 39596543 PMC: 11595136. DOI: 10.3390/ijms252212468.
Recent advances in anxiety disorders: Focus on animal models and pathological mechanisms.
Zhao H, Zhou M, Liu Y, Jiang J, Wang Y Animal Model Exp Med. 2023; 6(6):559-572.
PMID: 38013621 PMC: 10757213. DOI: 10.1002/ame2.12360.
Neurotoxicity of Silver Nanoparticles and Non-Linear Development of Adaptive Homeostasis with Age.
Antsiferova A, Kopaeva M, Kochkin V, Reshetnikov A, Kashkarov P Micromachines (Basel). 2023; 14(5).
PMID: 37241608 PMC: 10221892. DOI: 10.3390/mi14050984.